The company ABL Diagnostics announces its accounts for the financial year ending December 31, 2023.
Highlights :
ABL Diagnostics’ net accounting result as of December 31, 2023 stands at €54,000 compared to €1,106,000 in 2022. The 2022 result was driven by an exceptional increase in activity in the context of a pandemic during which the company marketed screening kits.
In line with its strategy to be the leader in personalized medicine in infectious diseases, ABL Diagnostics has continued and strengthened its development in 2023 in its key segment, genotyping by sequencing of HIV/AIDS and co-infections.
At the same time, ABL Diagnostics continued to expand its DeepChek® product range, which mainly targets infectious, viral and bacterial applications.
Turnover:
In a post-Covid context, ABL Diagnostics achieved a turnover of €5.6 million in 2023, down €3.1 million compared to the previous year. The turnover restated for sales of COVID 19 screening kits and excluding non-recurring effect is up by €215K, an increase of 4% compared to 2022. The 2023 turnover linked to COVID is lower 1% of ABL Diagnostics’ activity.
This growth excluding exceptional and non-recurring effects is mainly driven by DeepChek® HIV products, a strategic market for ABL Diagnostics, whose number of recurring customers increased by 33% over the year 2023.
 and a positive net accounting result in 2023 – Testimony of the ability of ABL Diagnostics to execute and advance its major strategic projects – 07/01/2024 at 6:00 p.m.: 00){kind=link}